Core Insights - On November 24, brokerages set target prices for listed companies, with notable increases for Fangsheng Pharmaceutical, Juhua Co., and Meihua Biological, showing target price increases of 46.38%, 38.81%, and 32.68% respectively, all belonging to the traditional Chinese medicine and chemical products industries [1][2]. Group 1: Target Price Increases - Fangsheng Pharmaceutical received a target price of 16.60 yuan, reflecting a target price increase of 46.38% [2]. - Juhua Co. was assigned a target price of 46.00 yuan, indicating a target price increase of 38.81% [2]. - Meihua Biological's target price was set at 13.44 yuan, with a target price increase of 32.68% [2]. - Other companies with significant target price increases include Toukeng Life (28.14% increase) and Yiling Pharmaceutical (18.30% increase) [2]. Group 2: Brokerage Recommendations - On November 24, a total of 23 listed companies received brokerage recommendations, with companies like Keshun Co., Jinhong Group, and Meihua Biological receiving one recommendation each [2]. - Fangsheng Pharmaceutical was covered for the first time by Guotai Junan Securities with an "Increase" rating [3]. - Other companies receiving first-time coverage include Linuo Pharmaceutical (Increase rating), Yinglian Co. (Increase rating), Huaxia Eye Hospital (Recommendation rating), and Yike Medical (Outperform rating) [3].

Core Insights - On November 24, 2023, brokerage firms set target prices for listed companies, with notable increases for Fangsheng Pharmaceutical, Juhua Co., and Meihua Biological, showing target price increases of 46.38%, 38.81%, and 32.68% respectively [1] Company Summaries - Fangsheng Pharmaceutical is in the traditional Chinese medicine sector and has the highest target price increase among the listed companies [1] - Juhua Co. operates in the chemical products industry and ranks second in target price increase [1] - Meihua Biological, also in the chemical products sector, ranks third with a significant target price increase [1] Brokerage Recommendations - A total of 23 listed companies received brokerage recommendations on November 24, 2023 [1] - Companies such as Keshun Co., Jinhong Group, and Meihua Biological received recommendations from one brokerage firm each [1]

Investment Rating - The report maintains a "Recommended" rating for the chemical industry [1] Core Views - The chemical industry is expected to benefit from the ongoing "anti-involution" measures, which may lead to a significant slowdown in global chemical capacity expansion. This shift is anticipated to enhance cash flow and dividend yields for companies in the sector, transforming them from cash-consuming entities to cash-generating ones [7][27] - The report highlights the potential for domestic substitutes for Japanese semiconductor materials due to rising tensions in Sino-Japanese relations, which could accelerate the domestic market's growth in this area [6] Summary by Sections Recent Trends - The chemical industry has shown a relative performance increase of 16.1% over the past 12 months, outperforming the CSI 300 index, which increased by 11.6% [4] Key Price Movements - DMC (Dimethyl Carbonate) prices rose to 4400 CNY/ton, up 14.29% week-on-week, driven by strong demand from the electrolyte sector [14] - Lithium battery electrolyte prices increased to 27000 CNY/ton, up 8.00% week-on-week, although profit margins for manufacturers are under pressure due to rising raw material costs [14] - Diammonium phosphate prices in East China reached 3850 CNY/ton, up 5.48% week-on-week, amid rising production costs [14] Investment Opportunities - The report identifies four key opportunities in the chemical sector: 1. Low-cost expansion, focusing on companies like Wanhua Chemical and Hualu Hengsheng [9] 2. Improved industry conditions, particularly in chromium salts and phosphate rock [10] 3. New materials with high growth potential, such as electronic chemicals and aerospace materials [11] 4. High dividend yields from state-owned enterprises in the chemical sector, including China Petroleum and China National Chemical [11] Company Tracking and Earnings Forecast - The report provides a detailed earnings forecast for key companies, indicating a positive outlook for several firms in the chemical sector, with many rated as "Buy" [28]

证券代码：600160 证券简称：巨化股份 公告编号：临 2025-51 浙江巨化股份有限公司 关于为控股子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 被担保人名称 本次新增担保金额 | 公司"） 5,475.80 万元 | | 浙江晋巨化工有限公司（以下简称"晋巨 | | --- | --- | --- | --- | --- | --- | | 担 保 象一 | 对 | 实际为其提供的担保余额 | 67,834.16 万元 | | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | 是 | 否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 | 肃巨化公司"） | | 甘肃巨化新材料有限公司（以下简称"甘 | | | | 本次新增担保金额 | 7000 | 万元 | | | 象二 | | 实际为其提供的担保余额 | 7000 | 万 ...

Core Viewpoint - The strong demand for lithium batteries is expected to sustain the price increase of PVDF, with projected demand for lithium-grade PVDF in China reaching approximately 78,700 tons in 2025, a year-on-year increase of 65.4% [1][2]. Industry Status - As of November 20, the mainstream market price of PVDF has risen from 49,000 CNY/ton at the beginning of November to 52,000 CNY/ton [1]. - The average market prices for PVDF used in lithium iron phosphate, ternary batteries, and membrane coating are reported at 60,000 CNY/ton, 119,500 CNY/ton, and 182,000 CNY/ton respectively, showing increases from mid-year lows [1][2]. Supply and Demand Dynamics - The downstream applications of PVDF primarily include lithium batteries, photovoltaics, coatings, and water films. In the first ten months of 2025, the total installed capacity for lithium iron phosphate batteries in China is 1,240 GWh, and for ternary batteries, it is 265 GWh [2]. - Assuming production remains stable in November and December, the estimated demand for lithium-grade PVDF could reach 78,700 tons in 2025, with a potential increase to 110,000 tons in 2026 if the growth rate in battery production continues [2]. Production Capacity Insights - The current effective production capacity of the PVDF industry is approximately 180,000 tons, with nominal new capacity reaching 157,000 tons. However, the actual new capacity may be lower than expected due to high barriers to entry in the supply chain [3]. - The supply chain for lithium-grade PVDF is concentrated among a few key players, including companies like Dongyue Group, Haohua Technology, and Juhua Co., Ltd. The actual supply increase may be significantly lower than anticipated due to the concentration of new effective capacity among existing suppliers [3].

Core Viewpoint - The chemical industry has faced declining profits for three consecutive years since 2022, with some sectors experiencing intense competition and overall losses. However, there are signs of potential recovery driven by industry self-regulation and improved supply-demand balance, which may enhance profitability [1]. Group 1: Industry Performance - As of November 20, 2025, the CSI Sub-Industry Chemical Theme Index rose by 0.17%, with notable increases in stocks such as Hongda Co. (+8.66%), Tongcheng New Materials (+4.35%), and Salt Lake Co. (+3.71%) [1]. - The basic chemical industry's price-to-book (PB) ratio is currently close to the bottom levels observed in 2019 and 2024, indicating that the valuation remains low [1]. Group 2: Future Outlook - Huatai Securities predicts that the basic chemical sector may see an upward trend starting in 2026, suggesting a focus on resilient domestic and foreign demand as well as improved market conditions [1]. - Since June 2025, there has been a significant decline in capital expenditure growth within the industry, which, combined with self-regulation efforts, is expected to facilitate supply-side coordination and the elimination of outdated capacity [1]. - Domestic demand is anticipated to recover further, supported by exports to Asia, Africa, and Latin America, leading to a gradual recovery in bulk chemicals [1]. Group 3: Investment Opportunities - The top ten weighted stocks in the CSI Sub-Industry Chemical Theme Index account for 44.83% of the index, with major players including Wanhua Chemical and Salt Lake Co. [2]. - Investors can also explore investment opportunities in the chemical sector through the Chemical ETF (159129), which closely tracks the CSI Sub-Industry Chemical Theme Index [2][3].

Group 1 - The company announced the resignation of its board secretary, Liu Yunhua, due to work adjustments [2][3] - Liu Yunhua will continue to serve as a director and in other roles within the company, ensuring that there are no unfulfilled commitments [3] - The company will promptly initiate the selection process for a new board secretary, with the current finance head, Wang Xiaoming, temporarily assuming the responsibilities [3]

Core Points - The company, Juhua Co., Ltd. (stock code: 600160), announced the resignation of its board secretary, Liu Yunhua, due to work adjustments [1] Summary by Category - **Company Announcement** - Juhua Co., Ltd. has received a written resignation report from its board secretary, Liu Yunhua [1]

Group 1 - Liu Yunhua has resigned as the Secretary of the Board of Directors of the company due to work adjustments, but he will continue to serve as a director and in other roles within the company [1] - The company's revenue composition for the period from January to December 2024 indicates that the chemical industry accounts for 84.88% of total revenue, while other businesses contribute 15.12% [1] Group 2 - The current market capitalization of the company is 93.8 billion yuan [2]

证券代码：600160 证券简称：巨化股份 公告编号：临 2025-50 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司将根据《上海证券交易所股票上市规则》《公司董事会秘书工作制度》 等有关规定，尽快完成董事会秘书的选聘工作。 为保证董事会工作的正常进行，公司在聘任新的董事会秘书之前，暂由公司 董事、财务负责人王笑明先生代行董事会秘书职责。 刘云华先生担任公司董事会秘书期间勤勉尽责，为公司的健康发展做出了积 极贡献。公司及董事会对此表示衷心感谢。 浙江巨化股份有限公司 关于董事会秘书离任的公告 重要内容提示： 浙江巨化股份有限公司（以下简称"公司"）董事会于近日收到公司董事会 秘书刘云华先生的书面辞职报告。因工作调整，刘云华先生辞去公司董事会秘书 职务。 一、提前离任的基本情况 | 姓名 | 离任职务 | 离任时间 | | | 原定任期 | 离任原因 | 是否继续在上 市公司及其控 | 具体职 务（如 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | ...